| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5894d694d4a784d601f503d79e518f2d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_50eb752940fa4aa36756a6bc9f6f3504 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-40 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 |
| filingDate |
2015-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0dbf6884b016b1b69fd8f0bcd1e94fcc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_516c043c96ef6440e654798a6cc3ed1e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_418f0345dd5d4c370de291f59f238f7d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_40be26b42b6a19e54fa198c779823a8e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_350492a54fc5443934c2e3f0a034f64b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eb6e27f54f6c939d8ce0ce37b538f0cd |
| publicationDate |
2016-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
AU-2015231713-A1 |
| titleOfInvention |
Methods for reducing cardiovascular risk |
| abstract |
The present invention provides methods for treating diseases and disorders that are associated with elevated levels of lipids and lipoproteins. The methods of the present invention comprise administering to a high cardiovascular risk patient a pharmaceutical composition comprising a PCSK9 inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody such as the exemplary antibody referred to herein as mAb316P or alirocumab. The methods of the present invention are useful for treating high cardiovascular risk patients with hypercholesterolemia and elevated levels of other atherogenic lipoproteins that are not adequately controlled by maximum tolerated dose statin therapy. In particular, the methods of the present invention are useful for reducing cardiovascular risk and lowering atherogenic lipoproteins in high cardiovascular risk patients within 12 months following an acute coronary syndrome event despite a maximum tolerated dose statin therapy. |
| priorityDate |
2014-03-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |